A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Inclusion Criteria: Participant is eligible for participation in the study if all of the following apply: * Participant has body mass index (BMI) range of 18.5 to 40.0 kg/m\^2, inclusive and weighs at least 50 kg at screening. * Female participant is not pregnant and the following condition apply: Not a woman of childbearing potential (WOCBP) * Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 120 days after Investigational Product (IP) administration. * Male participant must not donate sperm during the treatment period and for 120 days after investigational product (IP) administration. * Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 120 days after IP administration. * Participant has renal function defined by estimated glomerular filtration rate (eGFR) using modification of diet in renal disease (MDRD) formula: * Normal renal function with eGFR ≥ 90 mL/min per 1.73 m\^2, or * Mild renal impairment with eGFR 60 to \<90 mL/min per 1.73 m\^2, or * Moderate renal impairment with eGFR 30 to \<60 mL/min per 1.73 m\^2, or * Severe renal impairment as defined by the National Kidney Foundation and by eGFR \<30 mL/min per 1.73 m\^2 and not on hemodialysis (preferably not higher than 20 mL/min per 1.73 m\^2, with at least 50% of participants required to have eGFR ≤ 20 mL/min per 1.73 m\^2). * Participant has adequate venous access to allow collection of study-related samples. * Participant agrees not to participate in another interventional study while participating in the present study. Exclusion Criteria: Participant will be excluded from participation in the study if any of the following apply: * Participant has received any investigational therapy within 28 days or 7 half-lives, whichever is longer, prior to day -1. * Participant has any condition which makes the participant unsuitable for study participation. * Female participant who has been pregnant within 6 months prior to screening or breastfeeding within 3 months prior to screening. * Participant has a known or suspected hypersensitivity to gilteritinib or any components of the formulation used. * Participant has had previous exposure with gilteritinib. * Participant has any of the liver function tests (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and total bilirubin \[TBL\]) ≥ 1.5 × upper limit of normal on day -1. In such a case, the assessment may be repeated once. * Participant has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to IP administration. * Participant has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 1 week prior to day -1. * Participant has a mean corrected QT interval using Fridericia's formula (QTcF) of \> 450 msec (for male and female participants) on day -1. If the mean QTcF exceeds the limits above, 1 additional triplicate 12-lead electrocardiogram (ECG) may be taken. * Participant has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to day -1. * Participant has a history of consuming \> 14 units for male participants or \> 7 units for female participants of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism 3 months prior to screening or drug/chemical/ substance abuse within 1 year prior to screening (note: 1 unit = 12 ounces of beer, 4 ounces of wine, 1 ounce of spirits/hard liquor) or the participant tests positive for alcohol at screening or on day -1. * Participant has used any inducer of cytochrome P450 (CYP)3A metabolism (e.g., St. John's Wort, barbiturates and rifampin) in the 3 months prior to day -1. * Participant has had significant blood loss, donated ≥ 1 unit (450 mL) of whole blood or donated plasma within 7 days prior to day -1 and/or received a transfusion of any blood or blood products within 60 days. * Participant has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease or a family history of long QT syndrome. * Participant has a positive serology test for hepatitis A virus immunoglobulin M antibodies, hepatitis B surface antigen, hepatitis C virus antibodies or antibodies to human immunodeficiency virus type 1 and/or type 2 at screening. Participants with isolated hepatitis B core antibody (with negative hepatitis B surface antigen and negative hepatitis B surface antibody) may be eligible if hepatitis B DNA or hepatitis C RNA is undetectable. * Participant is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit. * Participant who has received any of the following drugs/products within 2 weeks prior to IP administration: * Strong or moderate CYP3A inhibitors (e.g., grapefruit, Seville oranges, ketoconazole or fluconazole) * Strong or moderate inhibitors and all inducers of P-glycoprotein * Substrates of multidrug and toxin extrusion 1 * Drugs that target serotonin 5-hydroxytryptamine receptor 1 or 5-hydroxytryptamine receptor 2B * Participant has a positive result for SARS-CoV-2 polymerase chain reaction (PCR) test during screening. * Participant has clinical signs and symptoms consistent with COVID-19 infection, e.g., fever, dry cough, dyspnea, sore throat, muscle or body aches and gastrointestinal symptoms or confirmed infection by appropriate SARS-CoV-2 PCR test within the 4 weeks prior to screening. Additional criteria for participants with mild, moderate and severe renal impairment: * Participant who has a history of any clinically significant illness (other than renal disease and conditions related to renal disease, such as stable diabetes and stable hypertension), medical condition or laboratory abnormality within 3 months prior to screening which precludes the participant from study participation. * Participant has a mean pulse rate \< 40 or \> 90 bpm; mean systolic blood pressure (SBP) \< 90 or \> 160 mmHg; mean diastolic blood pressure (DBP) \< 50 or \> 100 mmHg (measurements taken in triplicate after participant has been resting in the supine position for at least 5 minutes; pulse rate will be measured automatically) on day -1. If the mean blood pressure exceeds the limits above, 1 additional triplicate may be taken. * Participant who has had a change in dose regimen of medically required medication(s) in the 2 weeks prior to IP administration (permitted concomitant medications) and/or participant for whom dose changes are likely to occur during the study (minor dose changes are allowed in agreement with the sponsor) and/or participant has used nonpermitted concomitant medication(s) (including, but not limited to vitamins, hormonal contraceptives and natural and herbal remedies) in the 3 weeks prior IP administration, except for topical dermatological products (including corticosteroid products) and hormone replacement therapy (HRT). * Participant who requires or is likely to require any new concomitant medications during the course of the study. * Participant who has a renal disease secondary to malignancy. * Participant who has a fluctuating or rapidly deteriorating renal function within 4 weeks prior to IP administration, as indicated by strongly varying or worsening clinical and/or laboratory signs of renal impairment within the screening period. * Participant has a hemoglobin result of \< 8.5 g/dL. * Participant has a functioning kidney transplant. * Participant has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) within 3 months prior to day -1 or the participant tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids,cocaine and/or opiates) at screening or on day -1, unless the positive result is due to an approved prescription medication. Additional criteria for healthy participants with normal renal function: * Participant has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy. * Participant has any clinically significant abnormality following the physical examination, ECG and protocol-defined clinical laboratory tests at screening or on day -1. * Participant has a mean pulse rate \< 45 or \> 90 bpm; mean SBP \> 150 mmHg; mean DBP \> 90 mmHg (measurements taken in triplicate after participant has been resting in the supine position for at least 5 minutes; pulse rate will be measured automatically) on day -1. If the mean blood pressure exceeds the limits above, 1 additional triplicate may be taken. * Participant has used any prescribed or nonprescribed drugs (including, but not limited to vitamins, hormonal contraceptives and natural and herbal remedies) in the 2 weeks prior to IP administration, except for occasional use of acetaminophen (up to 2 g/day), topical dermatological products (including corticosteroid products) and HRT. * Participant has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) within 3 months prior to day -1 or the participant tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) at screening or on day -1.